国家卫计委:我国抗病毒药物供应保障充足

2018-01-21 佚名 新华社

国家卫计委:我国抗病毒药物供应保障充足

根据有民众反映有医院很难开到奥司他韦等抗感冒病毒药的问题,国家卫生计生委医政医管局副局长焦雅辉回应说,从当前来讲,我国抗病毒药物的供应保障充足,已要求全国医疗机构紧急采取临时采购措施,保障抗病毒药物供应。

焦雅辉在当天举行的国家卫计委新闻发布会上说,当前对于普通流感的治疗有口服药物奥司他韦(达菲),还有扎那米韦吸入粉雾剂,这两年我国又研制成功了对于重症流感患者使用的、可以静脉治疗的帕拉米韦。我们近年来在抗病毒治疗领域有了很强的底气,能够保障患者的安全。

中国疾病预防控制中心有关专家也表示,奥司他韦等神经氨酸酶抑制剂是流感的有效治疗药物,早期尤其是发病48小时之内应用抗流感病毒药物能显着降低流感重症和死亡的发生率。

焦雅辉说,我们注意到一些医院在流感高峰期开不到相关药品的情况,我们要求全国医疗机构紧急采取临时采购的措施,采购包括奥司他韦、扎那米韦和帕拉米韦在内的抗流感病毒药物。

据了解,国家卫计委要求各地卫生计生部门为医疗机构开启抗病毒药临时采购通道,保证医疗机构相关药品供应充足,不能够以任何理由影响患者对药品的获得。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2028720, encodeId=d48c2028e205c, content=<a href='/topic/show?id=dba72683e0b' target=_blank style='color:#2F92EE;'>#供应保障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26837, encryptionId=dba72683e0b, topicName=供应保障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Sat Mar 10 14:22:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668309, encodeId=fdc81668309b2, content=<a href='/topic/show?id=405f4086edb' target=_blank style='color:#2F92EE;'>#国家卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40867, encryptionId=405f4086edb, topicName=国家卫计委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26f26278927, createdName=zhangying8797, createdTime=Wed Jul 18 15:22:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292403, encodeId=16e21292403c3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354409, encodeId=161c135440944, content=<a href='/topic/show?id=4d723669096' target=_blank style='color:#2F92EE;'>#卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36690, encryptionId=4d723669096, topicName=卫计委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363336, encodeId=687e136333606, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2028720, encodeId=d48c2028e205c, content=<a href='/topic/show?id=dba72683e0b' target=_blank style='color:#2F92EE;'>#供应保障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26837, encryptionId=dba72683e0b, topicName=供应保障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Sat Mar 10 14:22:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668309, encodeId=fdc81668309b2, content=<a href='/topic/show?id=405f4086edb' target=_blank style='color:#2F92EE;'>#国家卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40867, encryptionId=405f4086edb, topicName=国家卫计委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26f26278927, createdName=zhangying8797, createdTime=Wed Jul 18 15:22:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292403, encodeId=16e21292403c3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354409, encodeId=161c135440944, content=<a href='/topic/show?id=4d723669096' target=_blank style='color:#2F92EE;'>#卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36690, encryptionId=4d723669096, topicName=卫计委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363336, encodeId=687e136333606, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2028720, encodeId=d48c2028e205c, content=<a href='/topic/show?id=dba72683e0b' target=_blank style='color:#2F92EE;'>#供应保障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26837, encryptionId=dba72683e0b, topicName=供应保障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Sat Mar 10 14:22:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668309, encodeId=fdc81668309b2, content=<a href='/topic/show?id=405f4086edb' target=_blank style='color:#2F92EE;'>#国家卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40867, encryptionId=405f4086edb, topicName=国家卫计委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26f26278927, createdName=zhangying8797, createdTime=Wed Jul 18 15:22:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292403, encodeId=16e21292403c3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354409, encodeId=161c135440944, content=<a href='/topic/show?id=4d723669096' target=_blank style='color:#2F92EE;'>#卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36690, encryptionId=4d723669096, topicName=卫计委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363336, encodeId=687e136333606, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-23 yahu
  4. [GetPortalCommentsPageByObjectIdResponse(id=2028720, encodeId=d48c2028e205c, content=<a href='/topic/show?id=dba72683e0b' target=_blank style='color:#2F92EE;'>#供应保障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26837, encryptionId=dba72683e0b, topicName=供应保障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Sat Mar 10 14:22:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668309, encodeId=fdc81668309b2, content=<a href='/topic/show?id=405f4086edb' target=_blank style='color:#2F92EE;'>#国家卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40867, encryptionId=405f4086edb, topicName=国家卫计委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26f26278927, createdName=zhangying8797, createdTime=Wed Jul 18 15:22:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292403, encodeId=16e21292403c3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354409, encodeId=161c135440944, content=<a href='/topic/show?id=4d723669096' target=_blank style='color:#2F92EE;'>#卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36690, encryptionId=4d723669096, topicName=卫计委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363336, encodeId=687e136333606, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2028720, encodeId=d48c2028e205c, content=<a href='/topic/show?id=dba72683e0b' target=_blank style='color:#2F92EE;'>#供应保障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26837, encryptionId=dba72683e0b, topicName=供应保障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Sat Mar 10 14:22:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668309, encodeId=fdc81668309b2, content=<a href='/topic/show?id=405f4086edb' target=_blank style='color:#2F92EE;'>#国家卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40867, encryptionId=405f4086edb, topicName=国家卫计委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26f26278927, createdName=zhangying8797, createdTime=Wed Jul 18 15:22:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292403, encodeId=16e21292403c3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354409, encodeId=161c135440944, content=<a href='/topic/show?id=4d723669096' target=_blank style='color:#2F92EE;'>#卫计委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36690, encryptionId=4d723669096, topicName=卫计委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363336, encodeId=687e136333606, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Jan 23 08:22:00 CST 2018, time=2018-01-23, status=1, ipAttribution=)]

相关资讯

流感肆虐,今冬抗过敏药占有率激增

今冬感冒(主要是流感)人群增加,发生过敏人群增多,带来抗过敏药市场大幅增长。

国家流感中心:全国流感仍处高峰阶段,不能放松警惕

国家流感中心近日流感监测结果显示,目前我国北方流感活动趋势略有下降,南方地区流感活动整体上升趋缓,流感样病例聚集性发热疫情呈下降趋势。监测数据显示,今年第2周,北方省份流感样病例标本中流感病毒检测阳性率为46.7%,略低于前一周,但仍高于过去三年同期水平;南方省份流感病毒检测阳性率为43.5%,高于前三周水平,也高于过去三年同期水平。全国流感活动仍处于较高水平。国家流感中心主任 王大燕:北方片整体

Mol Ther Nucleic Acids:内源microRNA组成的抗流感病毒防御体系

近年来,季节性流感高发,而且禽流感不断跨越物种屏障感染人,特别是H7N9和高致病性禽流感H5N1疫情时有发生,不仅严重威胁人类健康,而且给畜牧业生产造成重大损失,已成为严重的公共卫生问题。目前人类对流感病毒感染尚没有有效疗法。鉴于近两年流感病毒频繁暴发,所以研发有效抑制流感病毒感染的方法就显得尤为重要。

BioRxiv:流感可能只是通过呼吸传播不需要咳嗽和打喷嚏传播

根据今天公布的一项由马里兰大学领导的研究,流感病毒(流感)的传播比以前认为的要容易得多。

流感和重感冒后期市场,抗疱疹病毒药物临危受命

精彩内容在抗病毒药物中,广谱抗病毒药物是20世纪末发展较快的一类药物。抗疱疹病毒药物品种数量及用药金额的迅猛增长,客观上带动了抗病毒用药市场整体水平的提高。在2017年新颁布的《国家基本医疗保险、工伤保险和生育保险药品目录》中,广谱抗病毒核苷和核苷酸类药物有阿昔洛韦、泛昔洛韦、更昔洛韦、伐昔洛韦、利巴韦林等,其他抗病毒药物有膦甲酸钠等,基本覆盖了广谱抗病毒及抗疱疹病毒的常用药品。近期流感和重感

流感来袭儿科“停诊” 带给我们什么思考

入冬至今,全球多地出现流感高发现象,儿科停诊事件刷爆网络,成为公众关注事件,儿科医护问题再次摆在人们面前,不得不思考。